Douglas Tsao is the Managing Director at H.C. Wainwright & Co., LLC, a position he has held since November 2018. Based in the United States, he brings extensive experience in the financial sector, particularly in biopharmaceuticals and specialty pharmaceuticals. Prior to his current role, Douglas served as a Senior Analyst for U.S. Specialty Pharmaceuticals at Barclays from December 2011 to August 2018. He also held the position of Senior Analyst for U.S. Emerging Medical Devices at Barclays from March 2009 to December 2011. Earlier in his career, he worked as a Team Analyst for Healthcare Distribution & Technology at Lehman Brothers/Barclays and as an Administrative Fellow at Alta Bates Summit Medical Center. Douglas began his career as an Associate at Sunrise Securities/SCO Financial Group in 1999.